Login / Signup

Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers.

Pamela J MaxwellMelanie McKechnieChristopher W ArmstrongJudith M ManleyChee Wee OngJenny WorthingtonIan Geoffrey MillsDaniel B LongleyJames P QuigleyAmina ZoubeidiJohann S de BonoElena DeryuginaMelissa J LaBonteDavid J J Waugh
Published in: Molecular cancer research : MCR (2022)
Targeting hypoxia-induced signaling may extend the therapeutic benefit of enzalutamide, providing an improved treatment strategy for patients with resistant disease.
Keyphrases
  • prostate cancer
  • vascular endothelial growth factor
  • cancer therapy
  • drug delivery
  • combination therapy
  • newly diagnosed